secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001628280-25-014118
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus Q4 2024 net loss $25.8M; cash $14.4M; reviews strategic alternatives
--------------------------------------------------------------------------

- Q4 2024 net loss $25.8M vs $277.2M in Q4 2023 (prior-year includes $249.4M goodwill impairment); EPS -$0.87 vs -$12.59.
- Cash $14.4M at Dec 31; after Jan 2025 $21.4M net offering, expects runway into late Q3 2025.
- Board, with advisor, evaluating full range of strategic alternatives to maximize shareholder value.
- Business progress: EU Trilogue advanced; CA Rice Commission approved gene-edited Rice field trial; four Rice seed customer agreements.
- Cost-saving initiatives targeting $10M annualized run-rate, ~20% monthly cash use reduction; facility consolidation on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828025014118/0001628280-25-014118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828025014118/cbus-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-014118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer